Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
Cancer Medicine|June 20, 2024
Discriminating atypical parotid carcinoma and pleomorphic adenoma utilizing extracellular volume fraction and arterial enhancement fraction derived from contrast-enhanced CT imaging: A multicenter studyZhen-Yu Xu, Lin-Wen Huang, Yun-Jun Yang, et al.
European Journal of Medicinal Chemistry|August 31, 2023
Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugsXue-Mei Zheng, Yuan-Si Chen, Yu-Juan Ban, et al.
Molecular Cancer Therapeutics|December 15, 2017
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer ModelsJing Ai, Yi Chen, Xia Peng, et al.
Oncotarget|November 16, 2017
Association between alcohol consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studiesZheng He, Ting-Ting Zhao, Hui-Mian Xu, et al.
Oncotarget|November 9, 2017
Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trialsZheng He, Ting-Ting Zhao, Hui-Mian Xu, et al.
Frontiers in Chemistry|March 25, 2021
Discovery of New α-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological EvaluationShan-Kui Liu, Haifang Hao, Yuan Bian, et al.
Biomed Research International|April 30, 2016
Inhibitor of DNA Binding 1 Is Induced during Kidney Ischemia-Reperfusion and Is Critical for the Induction of Hypoxia-Inducible Factor-1αDan Wen, Yan-Fang Zou, Yao-Hui Gao, et al.
Diabetes, Obesity & Metabolism|August 9, 2016
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitusEric G Vajda, Douglas Logan, Kenneth Lasseter, et al.
Histopathology|April 18, 2014
ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancerZhao-Hua Gao, Chong Lu, Zhen-Ning Wang, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsShi-Yu Ye, Jia-Yi Li, Teng-Hui Li, et al.
Pageof 26